<?xml version="1.0" encoding="UTF-8"?>
<p>Given their point-of-care characteristics, LFI platforms have been widely used. In general, this method detects IgM and IgG antibodies in approximately 20 minutes, individually or simultaneously. Antibodies to glycoprotein S (spike) are analyzed from blood samples obtained by finger puncture without the need for sophisticated equipment or specialized professionals
 <xref rid="B8" ref-type="bibr">
  <sup>8</sup>
 </xref>. However, these tests are purely qualitative and can only indicate the presence or absence of SARS-CoV-2 antibodies
 <xref rid="B5" ref-type="bibr">
  <sup>5</sup>
 </xref>. Despite its potential value as a tool for pandemic control, the validation of LFI tests remains challenging
 <xref rid="B9" ref-type="bibr">
  <sup>9</sup>
 </xref>. The ability to assess their accuracy (sensitivity and specificity) as well as their ability to monitor immunity over time remains insufficient
 <xref rid="B10" ref-type="bibr">
  <sup>10</sup>
 </xref>. 
</p>
